EGFR and colorectal carcinoma: Our data suggest that CRC tumors with functional impairment of ARID1A function (as defined by the ARID1A signature) may also be resistant to anti-EGFR therapies, thus indicating that the prevalence of this phenotype may be broader than what ARID1A genomic mutation data would suggest.